{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:34:35Z","timestamp":1786988075993,"version":"build-2736575974"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22277142"],"award-info":[{"award-number":["22277142"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22477138"],"award-info":[{"award-number":["22477138"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018541","name":"Science Fund for Distinguished Young Scholars of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20160033"],"award-info":[{"award-number":["BK20160033"]}],"id":[{"id":"10.13039\/501100018541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010014","name":"Six Talent Peaks Project in Jiangsu Province","doi-asserted-by":"publisher","award":["2011-YY-004"],"award-info":[{"award-number":["2011-YY-004"]}],"id":[{"id":"10.13039\/501100010014","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005145","name":"Basic Research Program of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20211220"],"award-info":[{"award-number":["BK20211220"]}],"id":[{"id":"10.13039\/501100005145","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118222","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:58:40Z","timestamp":1759514320000},"page":"118222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["1-(3,4-Diaminophenyl)-1H-pyrrole-2-carboxylic acids as potent apo-IDO1 inhibitors exhibiting efficacy in syngeneic tumor mouse models"],"prefix":"10.1016","volume":"301","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6782-9380","authenticated-orcid":false,"given":"Yi","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shushan","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingbo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118222_bib1","article-title":"Immune escape: a critical hallmark in solid tumors","volume":"258","author":"Mortezaee","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2025.118222_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","article-title":"Next generation of immune checkpoint therapy in cancer: new developments and challenges","volume":"11","author":"Marin-Acevedo","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118222_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41698-021-00201-3","article-title":"Comprehensive molecular profiling of pulmonary pleomorphic carcinoma","volume":"5","author":"Nagano","year":"2021","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.ejmech.2025.118222_bib4","first-page":"451","article-title":"Immune checkpoint inhibitors: breakthroughs in cancer treatment","volume":"21","author":"Kong","year":"2024","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.ejmech.2025.118222_bib5","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118222_bib6","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118222_bib7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118222_bib8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-024-00700-2","article-title":"Primary and acquired resistance to immunotherapy with checkpoint inhibitors in NSCLC: from bedside to bench and back","volume":"39","author":"Mariniello","year":"2025","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejmech.2025.118222_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1546717","article-title":"Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors","volume":"16","author":"Alsaafeen","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118222_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2025.118222_bib11","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41571-024-00886-y","article-title":"Antiangiogenic\u2013immune-checkpoint inhibitor combinations: lessons from phase III clinical trials","volume":"21","author":"Kuo","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118222_bib12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-018-0644-y","article-title":"Targeting the IDO1 pathway in cancer: from bench to bedside","volume":"11","author":"Liu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118222_bib13","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4","volume":"210","author":"Holmgaard","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2025.118222_bib14","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00262-019-02394-w","article-title":"Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy","volume":"68","author":"Zahm","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejmech.2025.118222_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.678999","article-title":"IDO1 expression in ovarian cancer induces PD-1 in T cells via aryl hydrocarbon receptor activation","volume":"12","author":"Amobi-McCloud","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118222_bib16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.trecan.2017.11.005","article-title":"Inflammatory reprogramming with IDO1 inhibitors: turning immunologically unresponsive 'Cold' tumors 'Hot'","volume":"4","author":"Prendergast","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejmech.2025.118222_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fimmu.2018.00151","article-title":"The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy","volume":"9","author":"Hornyak","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118222_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00281-018-0702-0","article-title":"Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond","volume":"41","author":"Muller","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.ejmech.2025.118222_bib19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13045-021-01080-8","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy","volume":"14","author":"Tang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118222_bib20","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1073\/pnas.1719190115","article-title":"Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form","volume":"115","author":"Nelp","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2025.118222_bib21","doi-asserted-by":"crossref","first-page":"14538","DOI":"10.1021\/jacs.8b07994","article-title":"Mapping the binding trajectory of a suicide inhibitor in human indoleamine 2,3-dioxygenase 1","volume":"140","author":"Pham","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118222_bib22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/13543776.2018.1441290","article-title":"A patent review of IDO1 inhibitors for cancer","volume":"28","author":"Cheong","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2025.118222_bib23","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1080\/17460441.2020.1781811","article-title":"Advances in the discovery and development of selective heme-displacing IDO1 inhibitors","volume":"15","author":"Sun","year":"2020","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118222_bib24","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/1535-7163.MCT-20-0251","article-title":"Preclinical characterization of linrodostat mesylate, a novel, potent, and selective oral indoleamine 2,3-dioxygenase 1 inhibitor","volume":"20","author":"Balog","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118222_bib25","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1021\/acsmedchemlett.0c00668","article-title":"Discovery and preclinical evaluation of BMS-986242, a potent, selective inhibitor of indoleamine-2,3-dioxygenase 1","volume":"12","author":"Cherney","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118222_bib26","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/cbic.202000298","article-title":"Characterization of apo-form selective inhibition of indoleamine 2,3-dioxygenase","volume":"22","author":"Ortiz-Meoz","year":"2021","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2025.118222_bib27","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1021\/acsmedchemlett.1c00236","article-title":"Conformational-analysis-guided discovery of 2,3-disubstituted pyridine IDO1 inhibitors","volume":"12","author":"Cherney","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118222_bib28","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/13543776.2025.2510641","article-title":"A patent review of IDO1 inhibitors for cancer (2023-present): an update","volume":"35","author":"Qiu","year":"2025","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2025.118222_bib29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejmech.2017.06.039","article-title":"Discovery of potent IDO1 inhibitors derived from tryptophan using scaffold-hopping and structure-based design approaches","volume":"138","author":"Zou","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118222_bib30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ejmech.2017.09.025","article-title":"Discovery of imidazoleisoindole derivatives as potent IDO1 inhibitors: design, synthesis, biological evaluation and computational studies","volume":"140","author":"Zou","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118222_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111750","article-title":"Effective virtual screening strategy toward heme-containing proteins: identification of novel IDO1 inhibitors","volume":"184","author":"Zou","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118222_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128373","article-title":"Discovery of novel IDO1 inhibitors targeting the protein's Apo form through scaffold hopping from holo-IDO1 inhibitor","volume":"52","author":"Wu","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118222_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109233","article-title":"Combination of apatinib with apo-IDO1 inhibitor for the treatment of colorectal cancer","volume":"112","author":"Yu","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejmech.2025.118222_bib34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4049\/jimmunol.2100938","article-title":"Apo-form selective inhibition of IDO for tumor immunotherapy","volume":"209","author":"Liu","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2025.118222_bib35","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.4049\/jimmunol.2300545","article-title":"IDO1 inhibition promotes activation of tumor-intrinsic STAT3 pathway and induces adverse tumor-protective effects","volume":"212","author":"Yu","year":"2024","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2025.118222_bib36","doi-asserted-by":"crossref","first-page":"6633","DOI":"10.1021\/acs.jmedchem.5c00034","article-title":"Discovery and optimization of novel apo-IDO1 inhibitors by a pharmacophore-based structural simplification strategy","volume":"68","author":"Cen","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118222_bib37","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1233606","article-title":"Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay","volume":"341","author":"Martinez Molina","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118222_bib38","series-title":"BIOVIA Discovery Studio, Release 2019","year":"2019"},{"key":"10.1016\/j.ejmech.2025.118222_bib39","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0021-9258(19)77982-4","article-title":"Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity","volume":"263","author":"Takikawa","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118222_bib40","doi-asserted-by":"crossref","first-page":"29525","DOI":"10.1074\/jbc.M301700200","article-title":"Asp274 and his346 are essential for heme binding and catalytic function of human indoleamine 2,3-dioxygenase","volume":"278","author":"Littlejohn","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118222_bib41a","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.bmcl.2016.12.015","article-title":"Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors","volume":"27","author":"Markwalder","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118222_bib41b","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.bmcl.2018.01.010","article-title":"Development of a series of novel o-phenylenediamine-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors","volume":"28","author":"Williams","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118222_bib41c","series-title":"IDO inhibitors","author":"Balog","year":"2014"},{"key":"10.1016\/j.ejmech.2025.118222_bib41d","series-title":"Inhibitors of indoleamine 2,3-dioxugenase (IDO)","author":"Balog","year":"2014"},{"key":"10.1016\/j.ejmech.2025.118222_bib41e","series-title":"IDO inhibitors","author":"Markwalder","year":"2015"},{"key":"10.1016\/j.ejmech.2025.118222_bib41f","series-title":"IDO inhibitors","author":"Markwalder","year":"2015"},{"key":"10.1016\/j.ejmech.2025.118222_bib41g","series-title":"IDO inhibitors","author":"Markwalder","year":"2015"},{"key":"10.1016\/j.ejmech.2025.118222_bib41h","series-title":"Inhibitors of indoleamine 2,3-dioxugenase for the treatment of cancer","author":"Balog","year":"2016"},{"key":"10.1016\/j.ejmech.2025.118222_bib41i","series-title":"Inhibitors of indoleamine 2,3-dioxugenase for the treatment of cancer","author":"Balog","year":"2016"},{"key":"10.1016\/j.ejmech.2025.118222_bib41j","series-title":"Inhibitors of indoleamine 2,3-dioxugenase for the treatment of cancer","author":"Balog","year":"2016"},{"key":"10.1016\/j.ejmech.2025.118222_bib41k","series-title":"IDO inhibitors","author":"Balog","year":"2016"},{"key":"10.1016\/j.ejmech.2025.118222_bib42","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.2174\/092986711795656027","article-title":"Using an ancient tool for igniting and propagating immune tolerance: IDO as an inducer and amplifier of regulatory T cell functions","volume":"18","author":"Fallarino","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118222_bib43","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nri1806","article-title":"Regulatory T cells, tumour immunity and immunotherapy","volume":"6","author":"Zou","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2025.118222_bib44","doi-asserted-by":"crossref","first-page":"7398","DOI":"10.4049\/jimmunol.177.10.7398","article-title":"CD4+CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients","volume":"177","author":"Miller","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2025.118222_bib45","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/1535-7163.MCT-09-0628","article-title":"Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors","volume":"9","author":"Koblish","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118222_bib46","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1042\/BST0370605","article-title":"PCNA on the crossroad of cancer","volume":"37","author":"Stoimenov","year":"2009","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ejmech.2025.118222_bib47","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ijc.10645","article-title":"Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection","volume":"101","author":"Friberg","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118222_bib48","doi-asserted-by":"crossref","first-page":"8321","DOI":"10.1021\/jm401195n","article-title":"Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in lewis lung cancer (LLC) tumor-bearing mice","volume":"56","author":"Yang","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118222_bib49","doi-asserted-by":"crossref","first-page":"9161","DOI":"10.1021\/acs.jmedchem.9b01079","article-title":"N-benzyl\/aryl substituted tryptanthrin as dual inhibitors of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase","volume":"62","author":"Yang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118222_bib50","series-title":"AMBER 2016","author":"Case","year":"2016"},{"key":"10.1016\/j.ejmech.2025.118222_bib51","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2025.118222_bib52","series-title":"Gaussian 09 Revision D.01","author":"Frisch","year":"2009"},{"key":"10.1016\/j.ejmech.2025.118222_bib53","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2025.118222_bib54","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1016\/S0006-3495(98)77997-4","article-title":"Importance of explicit salt ions for protein stability in molecular dynamics simulation","volume":"74","author":"Ibragimova","year":"1998","journal-title":"Biophys. J."},{"key":"10.1016\/j.ejmech.2025.118222_bib55","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ejmech.2025.118222_bib56","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh Ewald: an N\u00b7log(N) method for Ewald sums in large systems","volume":"98","author":"Darden","year":"1993","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ejmech.2025.118222_bib57","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","article-title":"Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes","volume":"23","author":"Ryckaert","year":"1977","journal-title":"J. Comput. Phys."},{"key":"10.1016\/j.ejmech.2025.118222_bib58","doi-asserted-by":"crossref","first-page":"6363","DOI":"10.1063\/1.1667473","article-title":"Synchronization of trajectories in canonical molecular-dynamics simulations: observation, explanation, and exploitation","volume":"120","author":"Uberuaga","year":"2004","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ejmech.2025.118222_bib59","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1063\/1.448118","article-title":"Molecular dynamics with coupling to an external bath","volume":"81","author":"Berendsen","year":"1984","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ejmech.2025.118222_bib60","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1021\/ct200909j","article-title":"Routine microsecond molecular dynamics simulations with AMBER on GPUs. 1. generalized born","volume":"8","author":"G\u00f6tz","year":"2012","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2025.118222_bib61","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1021\/ct400314y","article-title":"Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. explicit solvent particle mesh ewald","volume":"9","author":"Salomon-Ferrer","year":"2013","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2025.118222_bib62","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1021\/ct400341p","article-title":"PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data","volume":"9","author":"Roe","year":"2013","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2025.118222_bib63","unstructured":"Origin, Version 8.0. OriginLab Corporation, Northampton, MA, USA."},{"key":"10.1016\/j.ejmech.2025.118222_bib64","unstructured":"The Open-Source Pymol, Version 2.3 Schr\u00f6dinger, LLC."},{"key":"10.1016\/j.ejmech.2025.118222_bib65","series-title":"BIOVIA Discovery Studio Visualizer","year":"2016"},{"key":"10.1016\/j.ejmech.2025.118222_bib66","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/prot.20033","article-title":"Exploring protein native states and large-scale conformational changes with a modified generalized born model","volume":"55","author":"Onufriev","year":"2004","journal-title":"Proteins"},{"key":"10.1016\/j.ejmech.2025.118222_bib67","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/(SICI)1096-987X(19990130)20:2<217::AID-JCC4>3.0.CO;2-A","article-title":"Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO)","volume":"20","author":"Weiser","year":"1999","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2025.118222_bib68","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","article-title":"End-point binding free energy calculation with MM\/PBSA and MM\/GBSA: strategies and applications in drug design","volume":"119","author":"Wang","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2025.118222_bib69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1006\/prep.2000.1214","article-title":"Expression and purification of recombinant human indoleamine 2,3-dioxygenase","volume":"19","author":"Littlejohn","year":"2000","journal-title":"Protein Expr. Purif."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:02:54Z","timestamp":1773147774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":79,"alternative-id":["S0223523425009870"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118222","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"1-(3,4-Diaminophenyl)-1H-pyrrole-2-carboxylic acids as potent apo-IDO1 inhibitors exhibiting efficacy in syngeneic tumor mouse models","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118222","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118222"}}